Search Results - "Gaggar, A"

Innate immunity in cystic fibrosis lung disease by Hartl, D, Gaggar, A, Bruscia, E, Hector, A, Marcos, V, Jung, A, Greene, C, McElvaney, G, Mall, M, Döring, G

“…Abstract Chronic lung disease determines the morbidity and mortality of cystic fibrosis (CF) patients. The pulmonary immune response in CF is characterized by…”
Get full text

Inhibition of airway proteases in cystic fibrosis lung disease by Griese, M, Kappler, M, Gaggar, A, Hartl, D

“…Progressive lung disease determines the morbidity and mortality of cystic fibrosis (CF) patients. CF lung disease is characterised by endobronchial…”
Get full text

Safety and efficacy of vesatolimod (GS‐9620) in patients with chronic hepatitis B who are not currently on antiviral treatment by Agarwal, K., Ahn, S. H., Elkhashab, M., Lau, A. H., Gaggar, A., Bulusu, A., Tian, X., Cathcart, A. L., Woo, J., Subramanian, G. M., Andreone, P., Kim, H. J., Chuang, W. L., Nguyen, M. H.

“…Summary Vesatolimod is an oral agonist of toll‐like receptor 7 designed to minimize systemic exposure and side effects. We assessed the safety and efficacy of…”
Get full text

Benzyloxycarbonyl-proline-prolinal (ZPP): Dual complementary roles for neutrophil inhibition by Russell, D.W., Hardison, M., Genschmer, K.R., Szul, T., Bratcher, P.E., Abdul Roda, M., Xu, X., Viera, L., Blalock, J.E., Gaggar, A., Noerager, B.D.

“…Neutrophil influx and activation contributes to organ damage in several major lung diseases. This inflammatory influx is initiated and propagated by both…”
Get full text

The role of matrix metalloproteinases in cystic fibrosis lung disease by GAGGAR, A, HECTOR, A, BRATCHER, P. E, MALL, M. A, GRIESE, M, HARTL, D

“…Significant airway remodelling is a major component of the increased morbidity and mortality observed in cystic fibrosis (CF) patients. These airways feature…”
Get full text

HBV/HDV co-infection microRNA profile: downregulation of anti-inflammatory and upregulation of pro-apoptotic and viral replication mircoRNAs is associated with HDV RNA replication and HBsAg levels by Carey, I, Shang, D, Bruce, M, Horner, M, Subramanian, M, Gaggar, A, Agarwal, K

Get full text

A phase1 study evaluating anti-PD-1 treatment with or without GS-4774 in HBeAg negative chronic hepatitis B patients by Gane, E, Gaggar, A, Nguyen, A.H, Subramanian, G.M, McHutchison, J.G, Schwabe, C, Dunbar, R

Get full text

HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg‐positive chronic hepatitis B patients by Wong, D., Littlejohn, M., Yuen, L., Jackson, K., Mason, H., Bayliss, J., Rosenberg, G., Gaggar, A., Kitrinos, K., Subramanian, M., Marcellin, P., Buti, M., Janssen, H. L. A., Gane, E., Locarnini, S., Thompson, A., Revill, P. A.

“…Summary Background Hepatitis B e antigen (HBeAg) seroconversion is a treatment endpoint for HBeAg‐positive CHB, and a necessary precursor to HBsAg loss…”
Get full text

Free radical-producing myeloid-derived regulatory cells: potent activators and suppressors of lung inflammation and airway hyperresponsiveness by Deshane, J, Zmijewski, J W, Luther, R, Gaggar, A, Deshane, R, Lai, J-F, Xu, X, Spell, M, Estell, K, Weaver, C T, Abraham, E, Schwiebert, L M, Chaplin, D D

“…Levels of reactive free radicals are elevated in the airway during asthmatic exacerbations, but their roles in the pathophysiology of asthma remain unclear. We…”
Get full text

Whole-genome deep sequencing of hepatitis B virus in chronic hepatitis B patients reveals single nucleotide variants associated with baseline HBV DNA levels and HBeAg status by Podlaha, O, Revill, P, Bhardwaj, N, Zhuo, L, Kitrinos, K, Gaggar, A, Jiang, Z, Marcellin, P, Locarnini, S, Chan, H.L

Get full text

On-treatment ALT flares are associated with HBsAg loss in genotype A chronic hepatitis B-infected patients treated with nucleotide analogue therapy by Wong, D, Walsh, R, Hammond, R, Yuen, L, Revill, P, Gaggar, A, Subramanian, M, Kitrinos, K, Locarnini, S, Thompson, A

Get full text

Whole-genome sequencing of patients achieving hepatitis B virus serum antigen loss following tenofovir disoproxil fumerate (TDF) and/or pegylated-interferon α-2a (PEG) therapy by Kleinstein, S.E, Marcellin, P, Chan, H.L, Shea, P.R, Gaggar, A, Kitrinos, K, Jump, B, Subramanian, G.M, Peterson, J, Goldstein, D.B

Get full text

Evaluation of serum HBV RNA and HBcrAg in chronic hepatitis B patients achieving different serological outcomes on tenofovir disoproxil fumarate (TDF) by Cathcart, A.L, Buti, M, Marcellin, P, Gaggar, A, Delaney, W, Kitrinos, K.M, van Bömmel, F

Get full text

Genomic Analyses of Host-Pathogen Interactions in Chronic Hepatitis B Virus Infection by Chaturvedi, N, Bartha, I, Kitrinos, K, Gaggar, A, Ge, D, Subramanian, M, Goldstein, D, Revill, P, Thompson, A, Fellay, J

Get full text

Durability of HBsAg loss with nucleotide analogs and pegylated interferon in patients infected with hepatitis B virus by Chan, H.L, Lok, A, Locarnini, S, Zoulim, F, Ghany, M, Dusheiko, G, Gaggar, A, Wu, G, Subramanian, G.M, Buti, M, Marcellin, P

Get full text

Viral kinetics in women of child bearing potential with chronic hepatitis B virus following treatment with tenofovir alafenamide or tenofovir disoproxil fumarate by Pan, C, Chang, T.-T, Bae, S.-H, Brunetto, M, Coffin, C, Lau, A, Mo, S, Flaherty, J.F, Gaggar, A, Subramanian, G.M, Nguyen, M.H, Gurel, S, Thompson, A, Gane, E.J

Get full text

Characterization of the intrahepatic immune response of virally-suppressed chronic hepatitis B patients to treatment with the oral TLR7 agonist GS-9620 by Boeijen, L, van Oord, G.W, Hou, J, van Campenhout, M.J, van der Heide-Mulder, M, Gaggar, A, Li, L, Fletcher, S.P, de Knegt, R.J, Boonstra, A

Get full text

Continued improvement in renal laboratory parameters in CHB patients treated with tenofovir alfenamide (TAF) compared with tenofovir disoproxil fumarate (TDF) over 96 weeks by Chuang, W.L, Agarwal, K, Hwang, J.S, Caruntu, F, Wong, F, Hann, H.W, Flaherty, J, Lau, A, Gaggar, A, Suri, V, Mo, S, Subramanian, G.M, Hui, A.J, Yatsuhashi, H, Lim, Y.S

Get full text

Improved bone and renal safety of switching from tenofovir disoproxil fumarate to tenofovir alafenamide: preliminary results from 2 phase 3 studies in HBeAg-positive and HBeAg-negative patients with chronic hepatitis B by Chan, H.L, Fung, S, Seto, W.K, Gane, E, Flaherty, J.F, Suri, V, Lin, L, Gaggar, A, Subramanian, G.M, Chuang, W.L, Agarwal, K, Janssen, H.L, Buti, M

Get full text

Combined GS-4774 and tenofovir therapy can improve HBV-specific T cell responses in patients with chronic active hepatitis B by Boni, C, Rossi, M, Vecchi, A, Laccabue, D, Giuberti, T, Alfieri, A, Andreone, P, Cursaro, C, Margotti, M, Mangia, A, Santoro, R, Piazzolla, V, Brunetto, M.R, Coco, B, Cavallone, D, Lau, A, Gaggar, A, Ferrari, C

Get full text